Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Clinical trial NCT02462525 · TERMINATED
Trial details
- NCT number
- NCT02462525
- Sponsor
- AbbVie
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-06
- Primary completion
- 2017-12-06
- Enrollment
- 74
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.